| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print April 10, 2008
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Pathology,* and Molecular and Comparative Pathobiology,|| and the Graduate Program in Immunology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; the W. Harry Feinstone Department of Molecular Microbiology and Immunology,¶ and the Department of Environmental Health Sciences, the Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; and the Cardiovascular Research Group, Faculty of Medicine, University of Calgary, Calgary, Canada
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
, transforming growth factor-β1, and IL-4 as well as histamine. The hallmark of the disease in IL-13 KO mice was the up-regulation of T-cell responses. CD4+ T cells were increased in IL-13 KO hearts both proportionally and in absolute number. Splenic T cells from IL-13 KO mice were highly activated, and myosin stimulation additionally increased T-cell proliferation. CD4+CD25+Foxp3+ regulatory T-cell numbers were decreased in the spleens of IL-13 KO mice. IL-13 deficiency led to decreased levels of alternatively activated CD206+ and CD204+ macrophages and increased levels of classically activated macrophages. IL-13 KO mice had increased caspase-1 activation, leading to increased production of both IL-1β and IL-18. Therefore, IL-13 protects against myocarditis by modulating monocyte/macrophage populations and by regulating their function.
We previously demonstrated that EAM in A/J mice carry hallmarks of Th2-like pathology. Blockade of interleukin (IL)-4 partially suppresses the development of EAM, indicating that IL-4 is cardiopathogenic in this strain.9 The importance of IL-4 in the pathogenesis of EAM suggests that other Th2 cytokines could also augment EAM pathology. Therefore, we postulated that IL-13, another Th2 cytokine, could synergize with IL-4, and that IL-13 knockout (KO) mice would develop reduced EAM and CVB3-induced myocarditis. However, our unexpected results presented in this article have led to the novel conclusion that IL-13 exerts protective effects in this autoimmune disease.
IL-13 is a pleiotropic cytokine produced by T-helper-type 2 (Th2) CD4+ T cells, CD8+ T cells, mast cells, dendritic cells, and eosinophils.11,12
IL-13 does not use the classical receptor for IL-4 (IL-4R
/c), but shares use of the alternative IL-4 receptor, consisting of IL-4R and the IL-13 receptor 1 (IL-13R1) subunit.13
In addition to the common receptor with IL-4, IL-13 has an additional receptor: IL-13R2, which possesses antagonistic decoy functions, in addition to unique signaling functions.14
There is growing evidence of unique physiological functions of IL-13, not shared by IL-4, in models of helminthic parasitism,15,16
schistosomiasis,17,18
lung immunity and atopy,19,20
and tumor immunity.21
T cells are not known to express functional IL-13R1 and so IL-13 is probably not directly acting on T cells. The main targets of IL-13 are monocytes/macrophages. IL-13 signaling in monocytes yielded a transcriptional profile unique and distinct from macrophages classically activated by interferon (IFN)-. IL-13 and IL-4 alternatively activated macrophages show distinct phenotypic changes: mannose receptor up-regulation, induction of selective chemokines, and expression of arginase. Also, IL-13 prevents lipopolysaccharide-dependent caspase-1 activity in monocytes, therefore decreasing production of IL-1 and IL-18. This role of IL-13 on macrophages contrasts with the activation of macrophages by IFN-: up-regulation of iNOS, as well as the proinflammatory cytokines IL-6, tumor necrosis factor (TNF)-, and IL-1.22,23
We report here that IL-13 KO mice on a BALB/c background developed significantly increased myosin- and CVB3-induced myocarditis. IL-13 reduces myocarditis by regulating monocyte/macrophage populations during EAM.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
IL-13 KO and IL-13/IL-4 DKO mice on the BALB/c background were generated in the laboratory of Andrew McKenzie, as described15,18 and were bred and maintained in the Johns Hopkins University School of Medicine conventional animal facility. IL-4 KO and WT BALB/c mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and maintained in the Johns Hopkins University School of Medicine conventional animal facility. All experiments were conducted on 6- to 8-week-old male mice. All methods and protocols involving mice were approved by the Animal Care and Use Committee of the Johns Hopkins University.
Induction of EAM
For the induction of EAM, we used the myocarditogenic peptide MyHC614–629 derived from the sequence of the murine cardiac myosin heavy chain (Ac-SLKLMATLFSTYASAD-OH)8,24
commercially synthesized by fMOC chemistry and purified by high performance liquid chromatography (Global Peptide, Fort Collins, CO). On days 0 and 7, mice received subcutaneous injections of 200 µg of MyHC614–629 peptide emulsified in complete Freund’s adjuvant (Sigma, St. Louis, MO) supplemented with 5 mg/ml of Mycobacterium tuberculosis, strain H37Ra (Difco, Detroit, MI). On day 0, mice additionally received 500 ng of pertussis toxin intraperitoneally (List Biologicals, Campbell, CA). For CVB3-induced myocarditis, IL-13 KO and WT BALB/c mice were inoculated intraperitoneally with 103 plaque-forming units of a heart-passaged stock of CVB3 (Nancy strain), originally obtained from the American Type Culture Collection (Manassas, VA), diluted in sterile phosphate-buffered saline (PBS) on day 0. Individual experiments were conducted at least three times with 7 to 10 mice per group.
Histopathology
Mice were evaluated for the development of EAM at the peak of disease on day 21 or in chronic stage of EAM at day 30 or chronic CVB3-induced myocarditis at day 35 after infection. Heart tissues were fixed in 10% phosphate-buffered formalin. Five-µm sections were cut longitudinally and stained with hematoxylin and eosin, and Masson’s trichrome for fibrosis. Myocarditis severity was evaluated by histopathological microscopic approximation of the percent area of myocardium infiltrated with mononuclear cells or fibrosis determined from five sections per heart according to the following scoring system: grade 0, no inflammation; grade 1, less than 10% of the heart section is involved; grade 2, 10 to 30%; grade 3, 30 to 50%; grade 4, 50 to 90%; grade 5, more then 90%. For CVB3-induced myocarditis the severity of the disease was assessed as the percentage of the heart section with inflammation compared with the overall size of the heart section, with the aid of a microscope eyepiece grid. Two independent researchers scored slides separately in a blinded manner.
Antibodies to Cardiac Myosin
Mice were bled on days 0 and 21 from the retro-orbital venous plexus using heparinized capillary tubes. Sera were collected by heart puncture on day 35 after infection of CVB3-induced myocarditis. Serum levels of MyHC614–629-reactive (EAM) or cardiac myosin (CVB3) antibodies were determined using microtiter plates coated with 0.5 µg of MyHC614–629 or cardiac myosin incubated with phosphatase-conjugated isotype-specific secondary antibodies. Adjusted optical density (OD) was calculated as follows: adjusted OD = mean OD of a sample – mean OD of a negative control. The autoantibody titer is expressed as the reciprocal of the highest serum dilution having an OD greater than that of the negative control serum plus three SD. Negative control serum consisted of pooled sera from 10 uninfected BALB/c mice.
Cytokine, Histamine, and Caspase-1 Enzyme-Linked Immunosorbent Assay (ELISA)
Half of the heart or spleen was snap-frozen on dry ice immediately after resection and stored at –80°C until homogenized in minimal essential medium plus 2% fetal bovine serum, debris cleared by centrifugation, and stored at –80°C until used in ELISA. Cytokine levels were measured in homogenized heart and spleen supernatants using Quantikine cytokine ELISA kits (R&D Systems, Minneapolis, MN), according to the manufacturer’s instructions. The limit of detection for the cytokine kits were as follows: IFN-, 2 pg/ml; transforming growth factor (TGF)-β1, 1.6 pg/ml; IL-1β, 3 pg/ml; IL-4, 2 pg/ml; IL-13, 1.5 pg/ml; IL-17, 5 pg/ml; IL-18, 25 pg/ml; histamine, 1.5 ng/ml. Heart cytokine and histamine levels were expressed as pg/g of heart tissue. Caspase-1 activity was measured from 5 x 106 splenocytes from IL-13 KO mice on day 21 of EAM. Splenocytes were snap-frozen and stored at –80°C until caspase-1 activity was measured. Caspase-1 activity was measured by the Casp-1/ICE fluorometric assay kit (BioVision, Mountain View, CA).
In Vitro MyHC614–629-Specific Proliferation
Single cell suspension was prepared from mice spleens. After enumeration in a hemocytometer and standardization of cell densities in RPMI 1640 and 10% fetal bovine serum, 2.5 x 105 responder cells were plated with 10 µg/ml of MyHC614–629 in triplicate in 96-well format. Control cells were cultured with media in the absence of MyHC614–629. All cells were incubated at 37°C, 5% CO2 for 48 hours. Proliferation assay plates were pulsed 24 hours before harvest with 1 µCi/well [3H]-methyl thymidine (GE Amersham, Buckinghamshire, UK), harvested onto glass filters, and specific radio-uptake detected on a Trilux β-direct counter (Packard, Waltham, MA).
Flow Cytometry
The heart was perfused at a constant flow of 14 ml/minute with cold PBS (Biofluids, Carlsbad, CA) for 2 minutes, and then digested with collagenase II (100 µg/ml; Sigma-Aldrich, St. Louis, MO) and protease XIV (50 µg/ml; Sigma- Aldrich) in PBS for 7 minutes at 37°C.25,26
After careful mincing, single cell suspensions were sequentially passed through 70-µm and 40-µm cell strainers (BD Falcon, Franklin Lakes, NJ). Splenocytes were also extracted into single cell suspension in 1x PBS, and red blood cells lysed by incubation in ACK lysis buffer (Biofluids). Cells were washed and FcRII/III blocked with CD16/32 (eBiosciences, San Diego, CA). Surface markers were stained with fluorochrome-conjugated mAbs to CD3
, CD4, CD8, CD11b (Mac1), CD11c, CD19, CD25, CD28, CD44, CD45, CD45R (B220), CD62L, CD69, CD71, CD80 (B7.1), CD86 (B7.2), CD117 (c-kit), CD152 (CTLA4), CD204 (SR-A), CD206 (MR), CD274 (PD-L1), DX5, F4/80, FcRI, Gr1 (Ly6G), Mac3, MHC Class II (I-A/I-E), and TCRβ (eBiosciences; BD Pharmingen, San Diego, CA; Biolegend, San Diego, CA; and AbD Serotec, Raleigh, NC). Treg cells were further stained by intracellular staining of Foxp3 with a kit according to manufacturer’s instructions (eBiosciences). Samples were acquired on a four-color dual-laser FACScalibur cytometer running the CellQuest software package or the LSR II quad-laser cytometer running FACSDiva (BD Immunocytometry, San Jose, CA).
Echocardiography
Trans-thoracic echocardiography was performed using the visualsonic Vevo 660 imaging system equipped with a 40 MHz transducer (VisualSonics Inc., Toronto, Canada). Conscious, previously trained mice were gently held in a supine position in the palm of the hand, as described.25,27 The left hemi-thorax was shaved and ultrasonic transmission gel (Parker Laboratories, Fairfield, NJ) was applied to the thorax. The heart was imaged in the two-dimensional mode in the parasternal short axis view. From this mode, an M-mode cursor was positioned perpendicular to the interventricular septum (IVS) and the left ventricular posterior wall (LVPW) at the level of the papillary muscles. From the M-mode, the left ventricular wall thickness and chamber dimensions were measured. For each mouse, three to five values for each measurement were obtained and averaged for evaluation. The left ventricular (LV) end diastolic dimension (LVEDD), LV end systolic dimension (LVESD), LV septal wall thickness at end diastole (IVSED) and end systole (IVSES), LV posterior wall thickness at end diastole (PWTED) and end systole (PWTES) were measured from a frozen M-mode tracing. Fractional shortening (FS %) is the percent change in LV cavity dimensions. Ejection fraction (EF %) represents stroke volume as a percentage of end diastolic LV volume. The heart rate is automatically determined from the M-mode image by positioning the first and second caliper point on two systolic phases. LV mass is determined automatically by the software or by using the following standard cube function formula: LV mass (mg) = 1.055 [(IVST + LVEDD + PWT)3 – (LVEDD)3] (1.055 is the specific gravity of the cardiac muscle).28 Relative wall thickness (RWT) indicates the overall thickness of the LV wall and is calculated as follows: (RWT) = 2 x PWTD/LVEDD.28,29
In Vivo Blocking of IL-4 and IL-13 during EAM
Mice were immunized with MyHC614–629 and received 2 mg of rat anti-mouse IL-4 mAb IgG1 clone 11B.11 (American Type Culture Collection) on days –1, 3, 6, 9, 12, 15, and 18. Control mice were injected with isotype control, anti-Escherichia coli β-galactosidase mAb IgG1 clone GL113 (kindly provided by Fred Finkelman, University of Cincinnati, Cincinnati, OH). Monoclonal Abs were purified from the concentrated hybridoma supernatants using a HiTrap protein G column (Supelco, Bellefonte, PA). For blocking of IL-13, mice were immunized with MyHC614–629 and injected with 100 µg of IL-13 mAb rat IgG2b clone 38213 (R&D Systems) on days 0, 4, 8, 12, and 16 of EAM. Normal rat IgG2b clone 141945 (R&D Systems) was used as an isotype control. All Abs were administered in sterile 1x PBS intraperitoneally.
Statistical Analyses
The Mann-Whitney U-test was used to compare EAM severity scores between treatment groups. Normally distributed data on continuous parametric axes were analyzed with the two-tailed Student’s t-test. Values of P < 0.05 were considered statistically significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
We found previously that blockade of IL-4 partially suppresses the development of myosin-induced myocarditis, indicating that IL-4 increases the severity of myocarditis in A/J mice.9
To investigate the role of another Th2 cytokine, IL-13, in myocarditis, we infected IL-13 KO and WT BALB/c controls with CVB3 and examined hearts for inflammation and viral replication during the early (day 21 after infection) and late phase (day 35 after infection) of chronic myocarditis. We found that IL-13 deficiency significantly increased the severity of chronic CVB3-induced myocarditis at day 35 after infection (P = 0.001) (Figure 1A)
. IL-13 deficiency was also associated with decreased survival. Only 40% of IL-13 KO mice survived past day 21 after infection, whereas none of the WT control mice had died by that time point (Figure 1B)
. Total IgG autoantibodies against cardiac myosin were also significantly increased in IL-13 KO mice, compared to WT controls (P < 0.01) (Figure 1C)
.
|
. Left ventricular end diastolic dimension (LVEDD) was not significantly changed at this time point (Figure 1D)
although DCM is usually not observed by histology until day 35 after infection. To exclude the possibility that increased viral replication or persistence resulted in increased myocarditis severity; we examined viral replication in IL-13 KO mice at several time points by plaque assay. We found no significant differences in viral replication in the hearts of IL-13 KO mice on day 7 (P = 0.85), on day 11 (P = 0.11), or on day 14 after infection (P = 0.15) (Figure 1, H–J)
. By day 14, CVB3 was already cleared from most of the WT and IL-13 KO hearts. Viral replication in heart tissue was not detectable at days 21 or 35 in either WT or IL-13 KO mice (data not shown). Thus, IL-13 reduces chronic myocarditis, autoantibody production, and heart failure after viral infection. Mice Deficient in IL-13 Develop Severe EAM with Increased CD45+ Cardiac-Infiltrating Cells in the Heart
To investigate the role of IL-13 in EAM, we immunized IL-13 KO BALB/c males with the myocarditogenic peptide MyHC614–629 emulsified in CFA.8
Consistent with the results from CVB3-induced myocarditis, IL-13 deficiency significantly increased the incidence and severity of EAM on day 21 (P < 0.0001) (Figure 2, A–C)
. In EAM hearts, total infiltrating CD45+ cells were significantly increased in IL-13 KO mice (Figure 2D)
. To test antigen-specific autoantibody responses, we examined the level of MyHC614–629-reactive serum antibodies by ELISA at day 21 of EAM. IL-13 KO mice developed significantly higher levels of MyHC614–629-reactive total IgG, IgG1, IgG2a, and IgG2b, compared to WT mice (Figure 2E)
. To additionally confirm that IL-13 is protective in EAM, we blocked IL-13 in WT BALB/c mice on days 0, 4, 8, 12, and 16 with anti-IL-13 mAb and also observed increased disease severity at day 21, compared to isotype control-treated mice (Figure 2F)
. Thus, IL-13 also limits myocarditis in EAM model.
|
All further studies were done on EAM. To analyze changes in cytokine expression at day 21 of EAM, we homogenized hearts of IL-13 KO and WT control mice and analyzed levels of IFN-, IL-1β, IL-4, IL-17, IL-18, TGF-β1, and histamine by ELISA. Th17 cells can mediate severe cardiac pathology when Th1 signaling is disrupted30,31
; blocking IL-17 with monoclonal antibody decreased myocarditis severity (our unpublished results). Therefore, we measured levels of intracardiac IL-17 to test the hypothesis that Th17 is the driving CD4+ subset mediating increased cardiac pathology in IL-13 KO EAM. However, we found that IL-17 was significantly lower in heart homogenates from IL-13 KO mice at day 21 of EAM, compared to WT BALB/c controls (Figure 3A)
.
|
, TGF-β1, IL-4, and also histamine in the hearts of IL-13 KO mice (Figure 3A)
. The most markedly increased cytokines were IL-18 and IL-1β; both were increased in hearts as well as in spleens of IL-13 KO mice (data not shown). Pro-IL-18 and pro-IL-1β are converted to their active forms by caspase-1. We found greatly increased caspase-1 activity in IL-13 KO splenocytes on day 21 of EAM (P = 0.0002) (Figure 3B)
. Thus, IL-13 probably protects against myocarditis by down-regulating caspase-1 activity and decreasing levels of active IL-1β and IL-18. IL-13 KO Mice Have Impaired Cardiac Function in the Chronic Stage of EAM
We have previously shown that fibrosis is associated with progression to DCM and heart failure.32,33
Although IL-13 is itself associated with fibrosis, its absence does not protect the heart against fibrotic changes caused by other profibrotic cytokines such as TGF-β1, IL-1β, IL-4, and also by histamine (Figure 3A)
. We have observed increased fibrosis of IL-13 KO mice on day 30 as evaluated by Masson’s Trichrome staining for the presence of collagen (Figure 3, C–E)
. Because IL-13 KO mice had more fibrotic changes in the heart than WT mice, we examined heart function in IL-13 KO mice by echocardiographic imaging the chronic stage of EAM on day 50. IL-13 KO mice demonstrated substantially impaired heart function (Figure 4, A and B)
, including increased LVEDD (P = 0.002) (Figure 4C)
, increased LVESD (P < 0.001) (Figure 4D)
, decreased %FS (P < 0.001) (Figure 4E)
, and decreased %EF (P < 0.001) (Figure 4F)
. Thus, IL-13 protects against development of severe myocarditis and DCM and cardiac failure in EAM.
|
To examine whether EAM in IL-4 KO mice would resemble EAM in IL-13 KO mice on the BALB/c background, we immunized IL-4 KO and WT BALB/c control mice with myocarditogenic peptide in complete Freund’s adjuvant. The severity of myocarditis in IL-4 KO mice on day 21 of EAM, as assessed by histology, was not significantly different compared to WT controls (Figure 5A)
. No significant differences were observed in intracardiac levels of IL-1β, IL-13, IL-18, or IFN-, although there was a tendency toward decreased IL-18 and IL-1β in IL-4 KO mice (P = 0.059 and 0.054) (Figure 5B)
. IL-4 mediates isotype-switching to IgG134
; IL-4 KO mice developed low levels of MyHC614–629-reactive IgG1 antibodies, but there was no significant difference compared to WT mice (Figure 5D)
. IL-4 KO mice had significantly increased levels of MyHC614–629-reactive IgG2a and IgG2b antibodies compared to WT mice (P < 0.05) (Figure 5, E and F)
. Since we have shown previously that blocking of IL-4 with anti-IL-4 mAb in A/J mice decreased disease severity,9
we blocked IL-4 in WT BALB/c mice with monoclonal antibodies and found no differences in the severity of myocarditis, similar to IL-4 KO mice (Figure 5G)
. Thus, in contrast to IL-13 deficiency, the absence of IL-4 in BALB/c mice had no significant effect on the severity of myocarditis or the level of proinflammatory cytokines in the heart during EAM.
|
To examine the interaction of IL-4 and IL-13 in EAM, we induced EAM in IL-13/IL-4 double-knockout (DKO) BALB/c mice. IL-13/IL-4 DKO mice showed significantly increased myocarditis compared to WT BALB/c controls (Figure 6A)
. IL-13/IL-4 DKO mice developed EAM with comparable histopathological severity to IL-13 KO mice (Figure 2A)
. Intracardiac IL-18 levels were significantly increased in IL-13/IL-4 DKO mice compared to WT controls (Figure 6B)
. Also similar to IL-13 KO mice, IL-1β levels were increased in the hearts of some of DKO mice compared to WT BALB/c mice; however, the difference did not reach statistical significance. IL-13/IL-4 DKO mice had no differences in levels of intracardiac IFN- and TGF-β1 (Figure 6B)
. Similar to IL-13 KO mice (Figure 2E)
, IL-13/IL-4 DKO mice showed significantly higher levels of MyHC614–629-reactive total IgG, IgG2a, and IgG2b antibodies, compared to WT (Figure 6C)
. In contrast to IL-13 KO mice, the levels of IgG1 were very low in IL-13/IL-4 DKO mice, similar to IL-4 KO mice, because IL-4 is a key cytokine in switching to IgG1.34
Similar to IL-13 KO mice (Figure 7D)
, IL-13/IL-4 DKO had decreased CD4+CD25+Foxp3+ regulatory T-cell (Treg) populations in spleen (Figure 6D)
. IL-13/IL-4 DKO mice had a disease phenotype very similar to that of IL-13 KO mice, indicating that IL-13 is a dominant Th2 cytokine in the regulation of EAM in BALB/c mice, compared to IL-4.
|
|
EAM in mice has been shown to be predominantly CD4+ T cell-driven.35,36
Therefore, we examined T-cell populations in IL-13 KO splenocytes with EAM. No differences were observed in the relative proportions of CD4+ or CD8+ T cells in the spleens of IL-13 KO mice when compared to WT mice at day 21 (Supplemental Table 1, see http://ajp.amjpathol.org). The effect of IL-13 deficiency on the activation phenotype of T cells in vivo was also determined. Flow cytometric analysis of splenic T cells at day 21 demonstrated increased T-cell activation in IL-13 KO mice, as determined by increased proportions of CD4+ and CD8+ T cells expressing low levels of CD62L (Figure 7A)
and high levels of CD28 (Figure 7B)
compared to WT mice. Furthermore, spleen cells from IL-13 KO and WT mice with EAM were assessed for antigen-specific proliferation by [3H]methyl-thymidine incorporation. Antigen-specific proliferation of IL-13 KO spleen cells in response to MyHC614–629 was significantly increased in comparison to the specific proliferation of WT BALB/c splenocytes (Figure 7C)
. To determine whether the severe EAM in the absence of IL-13 was attributable to changes in Treg populations, we examined the proportions of CD4+CD25+Foxp3+ Treg cells in the hearts and spleens of IL-13 KO mice on day 21 of EAM. We did not observe any differences in the proportion of intracardiac Tregs in IL-13 KO mice at this time point (data not shown). In contrast to the heart, a significant decrease in the proportions of CD4+CD25+Foxp3+ Tregs was observed in the spleens of IL-13 KO mice, compared to WT mice on day 21 of EAM (P = 0.016) (Figure 7D)
. To examine T-cell numbers in hearts of IL-13 KO mice, we cannulated the ascending aorta, perfused the hearts with 5% fetal bovine serum in PBS to flush out blood, and then continued perfusion with a digestion buffer containing protease and collagenase to be able to separate infiltrating leukocytes and analyzed the cell suspension by flow cytometry. Both proportional and absolute numbers of CD4+ T cells were substantially increased in IL-13 KO hearts (Figure 7E)
. Thus, splenic T cells from IL-13 KO mice were more activated and had greater antigen-specific proliferative responses than WT mice but had a decreased T-regulatory T-cell population. Additionally, CD4+ T cells were proportionally as well as absolutely increased in hearts of IL-13 KO mice.
IL-13-Deficient Mice Have Decreased Numbers of Alternatively Activated Macrophages in the Heart
Similar to the observed increase of CD4+ T cells in the hearts of IL-13 KO mice, we also found a significant increase in the numbers of DX5+TCRβ– NK cells (Tables 1 and 2)
. Although there were no differences in the proportions of CD19+ B cells or CD8+ T cells in the IL-13 KO hearts, absolute numbers of B cells and CD8+ T cells were significantly increased (Tables 1 and 2)
. Surprisingly, although absolute numbers of F4/80+CD11c– macrophages were increased in IL-13 KO hearts, F4/80+CD11c– macrophages were proportionally decreased in IL-13 KO hearts. To explain this relative decrease in macrophage numbers that did not correspond to the increase of proinflammatory cytokines in IL-13 KO hearts, we further examined the phenotype of monocytes and macrophages in IL-13 KO mice heart infiltrates (Figure 8A)
. CD204 (macrophage scavenger receptor) and CD206 (macrophage mannose receptor) are markers of alternative activation of macrophages.23
We observed decreased proportions of double-positive monocytes (CD11bhiF4/80–) bearing both CD204+ and CD206+ in the hearts of IL-13 KO mice at day 21 of EAM (Figure 8B)
. Moreover, the proportion of mature macrophages (F4/80+) expressing CD204 and/or CD206 was also decreased in IL-13 KO hearts (Figure 8C)
. On the other hand, we observed strikingly increased proportions of both monocytes and macrophages lacking both CD204 and CD206, which may indicate that classically activated macrophages were increased in hearts of IL-13 KO mice (Figure 8, D and E)
. These changes were observed in monocyte and macrophage phenotypes when calculated a variety of different ways, whether expressed as proportions of total CD45+ infiltrating leukocytes, as proportions of CD11b+F4/80– monocytes or F4/80+ macrophages (data not shown). Taken together, these data indicate that IL-13 has substantial influence over the polarized differentiation of monocyte and macrophage populations in the heart during EAM.
|
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The protective effect of IL-13 on myocarditis reported here agrees with the data published by Elnaggar and colleagues,37
who showed marked amelioration of rat EAM by delivery of an IL-13-Ig fusion gene vector. IL-13 has also been assigned protective roles in other autoimmune diseases. Reduced concentrations of IL-13 are found in the synovium and synovial fluids of rheumatoid arthritis patients.38
IL-13 was shown to decrease the levels of proinflammatory cytokines and chemokines produced by arthritic synovial tissue in vitro, mainly IL-1β, TNF-, and PGE2.39
In a mouse model of collagen-induced arthritis, IL-13 decreased the severity of arthritis by reducing TNF- and IL-1β levels, and reducing the total number of monocytes, lymphocytes, and polymorphonuclear cells in the joint. IL-13 treatment decreased arthritis when used either before or after disease induction.40
Human recombinant (hr) IL-13 has a protective effect in a rat model of experimental autoimmune encephalomyelitis, with decreased clinical and histological signs of disease.41
In the NOD mouse model of diabetes, hrIL-13 was shown to prevent insulitis and diabetes.42
Thus, IL-13 can be protective in several other autoimmune disease models.
In our study, the absence of IL-13 resulted in severe autoimmune myocarditis in both the viral model and EAM, progressing to DCM, cardiac dysfunction, and heart failure. We were unable to detect any significant differences in viral replication on days 7, 11, or 14 after infection in IL-13 KO mouse hearts, compared to WT mice. However, in some of the experiments, we have observed a nonsignificant tendency toward increased viral replication in IL-13 KO mice, although the difference never reached significance. Virus was undetectable at days 21 or 35 in both IL-13 KO and WT mice.
In the absence of virus, EAM in IL-13-deficient animals was associated with substantially increased CD45+ leukocyte infiltration of the heart; the absolute numbers of most immune cell types were increased at day 21 after infection. By day 30, much of the infiltration was replaced by severe fibrosis in IL-13 KO mice. We have previously shown that fibrosis is associated with progression to DCM and heart failure in both EAM and CVB3-induced myocarditis.32,43 IL-1β, IL-4, TGF-β1, and histamine are known to induce fibrosis,32,44,45 and were increased in IL-13 KO mice, which may account for the greater production of collagen by day 30 of EAM. In IL-13 KO mice increased fibrosis led to DCM with cardiac dysfunction and heart failure, as observed by echocardiographic imaging and decreased survival of IL-13 KO mice. Thus, IL-13 limits inflammation during myocarditis, and thereby protects against the development of fibrosis, DCM, and heart failure.
We observed up-regulation of both cellular and humoral adaptive immune responses in IL-13 KO mice. We observed increased absolute numbers of intracardiac CD19+ B cells and increased anti-myosin antibody production in IL-13 KO mice. T-cell responses were affected at multiple levels. In the absence of IL-13, activation of spleen CD4+ and CD8+ T cells increased, as did antigen-specific proliferation of splenocytes. Absolute, as well as proportional numbers of intracardiac CD4+ T cells were increased in the hearts of IL-13 KO mice. We considered the possibility that the expansion or induction of CD4+CD25+Foxp3+ Treg may be decreased in IL-13 KO EAM. Skapenko and colleagues46
showed that IL-13 is important in the extrathymic development of Tregs in an antigen-dependent manner. Although we did not observe a difference in the proportion of intracardiac Tregs on day 21 of EAM, we found significantly decreased numbers of CD4+CD25+Foxp3+ Tregs in the spleens of both IL-13 KO and IL-4/IL-13 DKO mice. This decrease of Tregs in the spleen suggests that IL-13 may be important in the induction or maintenance of Treg populations in the spleen, but it is not clear that it contributed to the protective effect of IL-13 in myocarditis.
IL-13 did not appear to protect against myocarditis by deviating Th1/Th2 responses. Guo and colleagues47
showed that T cells from IL-13 KO mice had decreased capacity to produce IL-4 in vitro, compared to WT mice. However, we have shown here that IL-13 KO mice have significantly increased levels of intracardiac IL-4 as well as IL-5 (data not shown) and increased levels of MyHC614–629-specific IgG1, indicating that IL-13 KO mice are able to generate Th2 responses. This is in agreement with a report from McKenzie and colleagues48
that showed that the defective Th2 responses in IL-13 KO mice are not readily apparent in vivo. Furthermore, IFN- and IgG2a levels, markers of a Th1 response, were increased in IL-13 KO mice. Thus, responses associated with both Th1 and Th2 immunity were up-regulated in the absence of IL-13. Strikingly, we observed that IL-4 KO mice developed a very different disease phenotype from that of IL-13 KO mice. Previously, we have blocked IL-4 in A/J mice by mAb and observed decreased EAM severity.9
Here, we observed that IL-4 KO mice on the BALB/c background developed mild myocarditis comparable to WT BALB/c mice on day 21. Blockade of IL-4 in WT BALB/c mice did not change the severity of myocarditis compared to isotype controls.
We are currently backcrossing the IL-4 KO allele to the A/J background to be able to address whether these observed differences are attributable to different background genetics in A/J and BALB/c mice. Although we did not observe statistically significant changes in myocarditis severity in IL-4 KO BALB/c mice, there was some indication that IL-4 may contribute to the pathogenesis of myocarditis because levels of intracardiac IL-1β and IL-18 tended to be lower in IL-4 KO mice. We had previously shown that both of these proinflammatory cytokines are important in myocarditogenesis; levels of IL-1β in the heart correlate well with histopathological assessment of disease severity.49,50
IL-4/IL-13 DKO mice developed severe cardiac infiltration, increased autoantibody responses, increased proinflammatory cytokines, and decreased Tregs in spleen—comparable with disease in IL-13 KO animals, suggesting a dominant role of IL-13 over IL-4 in disease pathogenesis. To help confirm the protective role of IL-13 in myocarditis, we also blocked IL-13 by mAb and observed a significant increase in myocarditis severity, compared to isotype controls, consistent with the knockout. Myocarditis in IL-13-treated animals was not as severe as in IL-13 KO mice, presumably because of incomplete neutralization of IL-13.
A novel Th subset, Th17, has been shown to be pathogenic in several autoimmune disease models.51-53 It was recently proposed that pathology in EAM is driven by IL-17-producing CD4+ T cells because severe myocarditis in T-bet KO mice was associated with increased IL-17 in the heart.30 We have found that blocking IL-17 significantly ameliorates EAM (unpublished observations); therefore, Th17 is an important pathway for the pathogenesis of myocarditis. However, we found decreased levels of IL-17 in the hearts and spleens (data not shown) of IL-13 KO mice, suggesting that Th17 CD4+ T cells are not responsible for increased inflammation in the absence of IL-13. Thus, this severe form of disease in IL-13 KO mice cannot be explained by enhanced IL-17 production. Clearly, the pathogenesis of myocarditis can be driven by multiple mechanisms.
Rather than deviating Th1/Th2 differentiation or increasing IL-17 production, lL-13 instead appears to down-regulate the production of proinflammatory cytokines in EAM. Although both B and T cells appear up-regulated in the absence of IL-13, the IL-13 receptor, IL-13R1, is not expressed on mouse T or B cells.54
Therefore, IL-13 has no direct signaling effects on mouse T and B cells and the change we observed is likely attributable to their regulation by other cell types that are dependent on IL-13. One possibility is that a major target for IL-13 is the innate immune system; by down-regulating the innate immune response, IL-13 may also down-regulate subsequent adaptive immune responses.
Potential targets for IL-13 include mast cells, natural killer (NK) cells, and dendritic cells. We observed increased proportions of NK cells and mast cells in the spleen and significantly increased numbers of NK cells and significantly increased histamine levels in the hearts of IL-13 KO mice on day 21 of EAM. However, macrophages are a primary source of IL-1β and IL-18, and are a major component of the heart infiltrate during both myosin- and CVB3-induced myocarditis.26,37 It was shown that monocytes incubated with IL-13 up-regulated or down-regulated 142 different genes.22 Some of these changes in gene regulation reflect the fact that IL-13 is able to increase the number of alternatively activated macrophages. Activation of macrophages in the presence of IL-4 or IL-13 induces expression of arginase-1, the mannose receptor (CD206), and the type A scavenger receptor (CD204).23 We have observed increases in the absolute numbers of macrophages in the heart infiltrate but proportionally compared to other components of the infiltrate, macrophages were decreased in hearts of IL-13 KO mice. We have found that the decrease is attributable to a reduction of CD206+ or CD204+ monocytes and macrophages that represent the alternatively activated subset, whereas the CD204–CD206– monocyte and macrophage populations were increased in the hearts of IL-13 KO mice. Thus, IL-13 deficiency is associated with an increase of classically activated macrophages in the heart and a decrease of alternatively activated macrophages.
One important group of genes that have been shown to be regulated by IL-13 in monocytes included several components of regulation of IL1, such as IL-1 receptor antagonist (IL-1ra) and caspase-1.22 We did not observe any differences in intracardiac production of IL-1ra in IL-13 KO mice (data not shown).55 Classically activated macrophages are a major source of proinflammatory cytokines, including IL-1. Caspase-1 is a key enzyme in converting IL-18 and IL-1β to their active forms, and we observed striking up-regulation of caspase-1 enzymatic activity on day 21 of EAM in splenocytes of IL-13 KO mice. This increased caspase-1 activity is likely responsible for increased levels of IL-1β and IL-18 in the absence of IL-13, corresponding with a shift in macrophage populations toward classically activated macrophages in the heart of IL-13 KO mice. These data might predict that alternatively activated macrophages mediate protection from disease, or that classically activated macrophages are a major pathophysiological effector in myocarditis.
Thus, IL-13 may limit the activation of effector T cells indirectly by altering activation, differentiation, proliferation, or survival of cells and proximal mediators of the innate autoimmune response. Most markedly, IL-13 protects against myocarditis by its multiple effects on monocytes and macrophages.
|
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by the National Institutes of Health (National Heart, Lung, and Blood Institute grants R01 HL70729, R01 HL67290, and HL087033).
Supplemental material for this article can be found on http://ajp.amjpathol.org.
Accepted for publication February 5, 2008.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
cpm (stimulated cpm – unstimulated cpm; values for individual animals are the mean of triplicate wells) for each group (n = 3); plus the SD. D: CD4+CD25+Foxp3+ Treg cells as a proportion of spleen lymphoid cells, in IL-13 KO (filled diamonds) or WT (open diamonds) animals at day 21 after infection. E: Intracardiac CD4+ T cells as a proportion of total CD45+ leukocytes (left) and calculated absolute numbers (right) in IL-13 KO (filled diamonds) or WT (open diamonds) animals at day 21 after infection. Horizontal bars indicate the mean of each group ± the SD. Statistics are by two-tailed Student’s t-test.